Learning Objectives:

1. Identify factors important in assessing risk for keloid development
2. Assess which treatment modalities are appropriate for keloids vs hypertrophic scars
3. Utilize different modalities to minimize pain in administering intralesional injections

Disclosures:

Donald Glass, MD, Presenter, is on the Advisory Board at AbbVie, Pfizer, and UCB. 

Faculty member does plan on discussing unlabeled/investigational uses of a commercial product: fluorouracil, pentoxifylline, dupilumab, flurandrenolide tape